Nova Mentis Life Science Corp.

NOVA

CA66980V1067

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 15:15:30 17/05/2024 BST			5-day change	1st Jan Change
0.015 ^CAD	0.00%		+50.00%	-25.00%

04-08	Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-26	Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors	CI

Liberty Leaf Holdings Ltd. has Changed its Name to Nova Mentis Life Science Corp

June 25, 2020 at 09:20 pm

Liberty Leaf Holdings Ltd. changed its name to Nova Mentis Life Science Corp.

Latest news about Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	04-08	CI
Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors	02-26	CI
Nova Mentis Life Science Corp. Announces Management Changes	01-03	CI
Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director	12-11	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
Nova Mentis Life Science Corp. Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome	29/08/23	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/08/23	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	31/05/23	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	25/04/23	CI
Nova Mentis Life Science Corp. Auditor Raises 'Going Concern' Doubt	24/04/23	CI
KGK Science Inc. Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial	18/04/23	CI
KGK Sciences Inc. Begins Recruiting Participants, on Behalf of Client Nova Mentis Life Science Corp. in First-Ever Clinical Trial Investigating Effects of Psilocybin on Adults Diagnosed with Fragile X Syndrome	18/04/23	CI
Nova Mentis Life Science Corp. Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial	11/04/23	CI
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial	14/02/23	CI
Nova Mentis Life Science Corp. Announces Board Changes	18/01/23	CI
Nova Mentis Receives Health Canada Approval for First-Of-its-Kind Psilocybin Clinical Trial	22/12/22	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	24/11/22	CI
Nova Mentis Enters into Research Services Contract with KGK Science for Phase II A Clinical Trial	17/11/22	CI
Nova Mentis Life Science Corp. Produces 1.5 mg Psilocybin Microdose Capsules	29/09/22	CI
Nova Mentis Life Science Corp. Forms A Tactical Partnership with KGK Science Inc. to Develop Its Psilocybin Drug Portfolio in Canada	15/09/22	CI
Nova Mentis Life Science Corp. Completes Production of Psilocybin Microdose Capsules	15/09/22	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	26/08/22	CI
Nova Mentis Life Science Corp. and University of Central Florida to Develop Saliva Serotonin Assay	09/06/22	CI
Nova Mentis Life Science Corp. Receives Controlled Substances Export Approval From The U.S. DEA for the Proprietary Psilocybin Drug NM 1001	07/06/22	CI
Nova Mentis Life Science Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/05/22	CI

Chart Nova Mentis Life Science Corp.

Duration

Period

More charts

Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The Company operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc.

Sector

Biotechnology & Medical Research

Calendar

28/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOVA MENTIS LIFE SCIENCE CORP.	-25.00%	1.64M
MODERNA, INC.	+35.22%	50.93B
IQVIA HOLDINGS INC.	-0.51%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.11%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.99%	18.9B
BIO-TECHNE CORPORATION	+7.98%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.45%	12.17B
MEDPACE HOLDINGS, INC.	+28.95%	12.16B